Evolent Health Stock-Based Compensation Growth & History (EVH)
Evolent Health's stock-based compensation was $39.7M for fiscal 2025.
View full Evolent Health company overviewEvolent Health annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $39.7M | −$7,000 | −0.02% |
| 2024 | 2024-12-31 | $39.7M | −$755,000 | −1.86% |
| 2023 | 2023-12-31 | $40.5M | $6.5M | +19.19% |
| 2022 | 2022-12-31 | $34.0M | $17.3M | +103.35% |
| 2021 | 2021-12-31 | $16.7M | $2.1M | +14.41% |
| 2020 | 2020-12-31 | $14.6M | −$1.0M | −6.48% |
| 2019 | 2019-12-31 | $15.6M | −$2.0M | −11.31% |
| 2018 | 2018-12-31 | $17.6M | −$2.8M | −13.84% |
| 2017 | 2017-12-31 | $20.4M | $1.8M | +9.85% |
| 2016 | 2016-12-31 | $18.6M | $3.9M | +26.30% |
| 2015 | 2015-12-31 | $14.7M | $14.7M | — |
| 2014 | 2014-12-31 | $0 | −$91,000 | — |
| 2013 | 2013-12-31 | $91,000 | — | — |
Evolent Health quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.2M | $3.6M | +31.27% |
| Q1 2026 | 2026-03-31 | $10.6M | −$432,000 | −3.90% |
| Q4 2025 | 2025-12-31 | $2.4M | — | — |
| Q3 2025 | 2025-09-30 | $14.7M | $266,000 | +1.85% |
| Q2 2025 | 2025-06-30 | $11.6M | −$1.1M | −8.52% |
| Q1 2025 | 2025-03-31 | $11.1M | −$7.7M | −41.01% |
| Q3 2024 | 2024-09-30 | $14.4M | $4.2M | +41.03% |
| Q2 2024 | 2024-06-30 | $12.7M | $3.7M | +41.19% |
| Q1 2024 | 2024-03-31 | $18.8M | $8.1M | +75.41% |
| Q4 2023 | 2023-12-31 | $10.6M | −$4.0M | −27.53% |
| Q3 2023 | 2023-09-30 | $10.2M | $3.2M | +46.20% |
| Q2 2023 | 2023-06-30 | $9.0M | $2.0M | +27.87% |
| Q1 2023 | 2023-03-31 | $10.7M | $5.4M | +100.34% |
| Q4 2022 | 2022-12-31 | $14.6M | $9.7M | +195.16% |
| Q3 2022 | 2022-09-30 | $7.0M | $2.6M | +59.09% |
| Q2 2022 | 2022-06-30 | $7.0M | $3.4M | +91.95% |
| Q1 2022 | 2022-03-31 | $5.3M | $1.6M | +44.25% |
| Q4 2021 | 2021-12-31 | $5.0M | $726,000 | +17.16% |
| Q3 2021 | 2021-09-30 | $4.4M | $1.2M | +38.91% |
| Q2 2021 | 2021-06-30 | $3.7M | −$50,000 | −1.35% |
| Q1 2021 | 2021-03-31 | $3.7M | $198,000 | +5.64% |
| Q4 2020 | 2020-12-31 | $4.2M | $3.7M | +638.39% |
| Q3 2020 | 2020-09-30 | $3.2M | −$2.6M | −45.05% |
| Q2 2020 | 2020-06-30 | $3.7M | −$1.0M | −22.04% |
| Q1 2020 | 2020-03-31 | $3.5M | −$1.0M | −22.68% |
| Q4 2019 | 2019-12-31 | $573,000 | −$4.5M | −88.65% |
| Q3 2019 | 2019-09-30 | $5.8M | $1.7M | +42.28% |
| Q2 2019 | 2019-06-30 | $4.8M | $32,000 | +0.68% |
| Q1 2019 | 2019-03-31 | $4.5M | $742,000 | +19.55% |
| Q4 2018 | 2018-12-31 | $5.0M | $784,000 | +18.38% |
| Q3 2018 | 2018-09-30 | $4.0M | −$1.7M | −29.10% |
| Q2 2018 | 2018-06-30 | $4.7M | −$642,000 | −11.98% |
| Q1 2018 | 2018-03-31 | $3.8M | −$1.3M | −25.65% |
| Q4 2017 | 2017-12-31 | $4.3M | −$495,000 | −10.40% |
| Q3 2017 | 2017-09-30 | $5.7M | $909,000 | +18.94% |
| Q2 2017 | 2017-06-30 | $5.4M | $650,000 | +13.80% |
| Q1 2017 | 2017-03-31 | $5.1M | $769,000 | +17.74% |
| Q4 2016 | 2016-12-31 | $4.8M | $566,000 | +13.50% |
| Q3 2016 | 2016-09-30 | $4.8M | $417,000 | +9.52% |
| Q2 2016 | 2016-06-30 | $4.7M | −$1.4M | −23.46% |
| Q1 2016 | 2016-03-31 | $4.3M | $4.3M | — |
| Q4 2015 | 2015-12-31 | $4.2M | — | — |
| Q3 2015 | 2015-09-30 | $4.4M | $4.4M | — |
| Q2 2015 | 2015-06-30 | $6.2M | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
Evolent Health stock-based compensation trends
Over the last five fiscal years, Evolent Health's stock-based compensation increased from $14.6M to $39.7M, a change of $25.1M. The latest reported quarter, Q2 2026, shows $15.2M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evolent Health source filings ↗